COVID-19 convalescent plasma donors: impact of vaccination on antibody levels, breakthrough infections and reinfection rate

  1. La Raja Massimo
  2. Pacenti Monia
  3. Grimaldi Ileana
  4. Boldrin Caterina
  5. Cattai Margherita
  6. Solimbergo Erica
  7. Battisti Anna
  8. Scomazzon Michele
  9. Roman Alberto
  10. Lazzaro Anna Rosa
  11. Vicari Stefano
  12. Terzariol Stefano
  13. De Silvestro Giustina

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

From April 2020 through May 2021 in Padova Province 3395 COVID-19 recovered patients were recruited as potential convalescent plasma donors and tested for SARS-CoV-2 antibodies. Since January 2021 COVID-19 vaccination campaign began in Italy, the impact of vaccination on antibody levels and suspect vaccine breakthrough infections in these subjects were investigated. Post-vaccination anti-Sars-Cov-2 antibody level in 54 previously infected subjects had an exponential increase compared to pre-vaccination level regardless of the number of vaccine doses. However after 100 days from vaccination SARS-CoV-2 antibody level tends to decline. Post-vaccination primary infections were detected in 15 cases, with 3 possible breakthrough infections after a full vaccination course. In these cases, antibody response after infection was present but weaker than the one of subjects vaccinated after natural infection. A trend toward stronger antibody response was observed with increasing distance between natural infection and vaccination. Additionally, 2 cases of asymptomatic reinfections are also discussed.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.07.13.21260414: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: All participants signed informed consent at recruitment before SARS-CoV-2 antibody testing as a part of the clinical study on CP approved by the Ethics Committee of the Padova University Hospital (1).
    IRB: All participants signed informed consent at recruitment before SARS-CoV-2 antibody testing as a part of the clinical study on CP approved by the Ethics Committee of the Padova University Hospital (1).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    On CP donations an in vitro microneutralization method was used for neutralizing antibodies-NA-assessment.
    antibodies-NA-assessment
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.07.13.21260414v1 on medRxiv